Generic Name and Formulations:
Acamprosate calcium 333mg; e-c tabs.
Indications for CAMPRAL:
Maintenance of abstinence from alcohol in alcohol-dependent patients who are abstinent at treatment initiation, in conjunction with psychosocial support.
666mg 3 times daily. Renal impairment (CrCl 30–50mL/min): initially 333mg 3 times daily. Begin therapy during abstinence; continue during relapse.
Severe renal impairment (CrCl≤30mL/min). Sulfite allergy.
Moderate renal impairment (CrCl 31–50mL/min); reduce dose. Not a treatment for withdrawal symptoms. Monitor for suicidal ideation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
GI upset, myalgia/arthralgia, headache, rash, syncope, impotence, edema, palpitations; rare: kidney failure, suicidality.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment